Advocacy intelligence hub — real-time data for patient organizations
HYMPAVZI: FDA approved
routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX inhibitors
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
HYMPAVZI
(MARSTACIMAB-HNCQ)Orphan drugPfizer Laboratories Div Pfizer Inc